TIDMAGL
RNS Number : 9730D
Angle PLC
25 February 2020
For immediate release 25 February 2020
ANGLE plc ("the Company")
ANGLE and BioView to Present Combined Solution for Circulating
Tumor Cell Detection and Analysis at Molecular Med Tri-Con 2020 in
San Francisco, 4 March 2020
ANGLE plc, (AIM:AGL OTCQX:ANPCY) a world leading liquid biopsy
company, and BioView Ltd. (TASE:BIOV), a provider of automated cell
imaging and analysis solutions, announced today that they will
present results of their recent collaboration to develop an
integrated workflow for identifying clinical biomarkers on
circulating tumor cells (CTCs) at the Molecular Med Tri-Con 2020
Conference in San Francisco (Tri-Con) on March 4, 2020.
The collaboration combines ANGLE's Parsortix system, which
enables a liquid biopsy (a simple blood test) to be used to provide
the cancer cells for analysis in a format suitable for multiple
subsequent downstream analyses, and BioView's Duet imaging and
analysis system, which provides all essential functions required to
transform resource-heavy manual CTC detection and analysis into an
automated, high-throughput, high-capacity process that is suited to
clinical practice. Through the collaboration, ANGLE and BioView are
integrating their best-in-class technologies to create a workflow
for the isolation and characterisation of CTCs with the goal of
providing clinical insights to physicians such as the expression of
HER-2 (in relation to the drug Herceptin) and PD-L1 (in relation to
immunotherapy drugs).
The presentation, "Combining Cell Harvesting and Imaging
Technologies for CTC Liquid Biopsy Sample-to-Answer", will be
presented by Anne-Sophie Pailhes-Jimenez, ANGLE Senior R&D
Group Leader at Molecular Med Tri-Con 2020.
The Tri-Con Conference is a leading industry event in the
personalised medicine space. The upcoming event will focus on
emerging therapeutic, diagnostic, and technology approaches to
advance precision medicine. The presentation will take place at
12.25 on March 4 in the Muscone South Convention Centre, San
Francisco.
ANGLE's Parsortix system and BioView's Duet system and
associated workflows are available for research use only as
products that can be implemented in customers' laboratories or
provided as an ANGLE service with blood samples processed and
biomarker information reported.
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"The combination of two leading-edge technologies, ANGLE's
Parsortix CTC enrichment system and BioView's imaging and detection
technology, provides a powerful sample-to-answer workflow for the
characterisation of CTCs. Such standardised workflows will help
support the development of a wide range of clinical applications
for CTCs."
For further information ANGLE:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
finnCap Ltd (NOMAD and Joint Broker)
Corporate Finance - Carl Holmes, Simon Hicks, Max Bullen-Smith
ECM - Alice Lane, Sunila de Silva +44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes, Nigel Birks, Andrew Craig, Chris Lee +44 (0) 203 705 9330
FTI Consulting
Simon Conway, Ciara Martin +44 (0) 203 727 1000
Matthew Ventimiglia (US) +1 (212) 850 5624
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world leading liquid biopsy company with
sample-to-answer solutions. ANGLE's proven patent protected
platforms include a circulating tumor cell (CTC) harvesting
technology and a downstream analysis system for cost effective,
highly multiplexed analysis of nucleic acids and proteins.
ANGLE's cell separation technology is called the Parsortix(R)
system, and it enables a liquid biopsy (a simple blood test) to be
used to provide the cells of interest to the user in a format
suitable for multiple types of downstream analyses. The system is
based on a microfluidic device that captures cells based on a
combination of their size and compressibility. The system is
epitope independent and can capture all types of CTCs as well as
CTC clusters in a viable form (alive). CTCs enable the complete
picture of a cancer to be seen as being a complete cell they allow
DNA, RNA and protein analysis and the live cells harvested can be
cultured. The Parsortix technology is the subject of 24 granted
patents in Europe, the United States, China, Australia, Canada,
India, Japan and Mexico with three extensive families of patents
are being progressed worldwide. The Parsortix system has a CE Mark
in Europe for the indicated use and FDA clearance is in process for
the United States with a 400 subject clinical study and associated
analytical studies in metastatic breast cancer. ANGLE is seeking to
be the first ever FDA cleared CTC harvesting system and only the
third ever FDA cleared liquid biopsy test. ANGLE has already
undertaken two separate 200 subject clinical studies under a
program designed to develop an ovarian cancer pelvic mass triage
test, with the results showing best in class accuracy (ROC-AUC) of
95.1%. The pelvic mass triage assay has undergone further
refinement and optimisation, and is currently in the process of a
200 patient clinical verification study.
ANGLE's technology for the multiplex evaluation of proteins and
nucleic acids of all types is called the HyCEAD(TM) Ziplex(R)
platform and is based on a patented flow through array technology.
It provides for low cost, highly multiplexed, rapid and sensitive
capture of targets from a wide variety of sample types. A
proprietary chemistry approach (the HyCEAD method) allows for the
capture and amplification of over 100 biomarkers simultaneously in
a single reaction. The HyCEAD Ziplex system is extremely sensitive
and is ideal for measuring gene expression and other markers
directly from Parsortix harvests and was used in the ovarian cancer
pelvic mass triage test to achieve best in class accuracy (ROC-AUC)
of 95.1%.
ANGLE's proprietary technologies can be combined to provide
automated, sample-to-answer results in both centralised laboratory
and point-of-use cartridge formats.
ANGLE has established formal collaborations with world-class
cancer centres and major corporates such as Abbott, Philips and
QIAGEN, and works closely with leading CTC translational research
customers. These Key Opinion Leaders (KOLs) are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. The body of evidence as to the benefits of the Parsortix
system is growing rapidly from our own clinical studies in
metastatic breast cancer and ovarian cancer and also from KOLs with
28 peer-reviewed publications and numerous publicly available
posters, available on our website.
About BioView Ltd www.bioview.com
For nearly two decades BioView has been developing,
manufacturing and marketing innovative automated cell imaging and
analysis solutions, for use in cytology, cytogenetic, pathology
clinical and research laboratories. Founded and managed by experts
in the areas of medical devices, clinical and research
applications, and automated scanning systems, BioView leverages its
knowledge and expertise in the development of a dedicated scanner,
designed to address the specific challenges of CTC imaging,
analysis and reporting.
BioView is a publicly traded company on the Tel Aviv Stock
exchange, and currently has strategic collaborations underway with
international scientific leaders and institutions. For more
information about the BioView technology, and press related issues,
please contact info@bioview.co.il or visit our website at
www.bioview.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAGZGZZGDLGGZZ
(END) Dow Jones Newswires
February 25, 2020 02:00 ET (07:00 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2024 to May 2024
Angle (LSE:AGL)
Historical Stock Chart
From May 2023 to May 2024